Ligand is a high-growth company with economic rights to some of the world's most important medicines.
Ligand’s portfolio covers a diverse array of therapeutic areas, partners and underlying technologies with many products in late stage development.
Ligand’s investment in new technology has resulted in cutting-edge innovations that are making major drugs possible.
Ligand has multiple technologies and unpartnered programs available for out-licensing.
Jun 12, 2019 • 9:00 AM EDT
Ligand Subsidiary Vernalis and PhoreMost Limited Announce Drug Discovery Collaboration for Novel Oncology Target
May 17, 2019 • 9:00 AM EDT
Ligand Licenses VER250840 to Cumulus Oncology
May 6, 2019 • 9:00 AM EDT
Ligand Acquires Milestone and Royalty Rights to SB206 from Novan, Inc.
Jun 6, 2019 • 8:30am PDT
3911 Sorrento Valley Boulevard, Suite 110, San Diego, CA 92121
See all events
May 29, 2019
May 2, 2019 • 4:30pm EDT
$SAGE announces U.S. Drug Enforcement Administration scheduling of ZULRESSO™ (brexanolone) injection; on track for… https://t.co/yG32YL8KYY
Ligand highlights OmniClic in presentation titled “Fixed Light Chain Transgenic Chicken for Bispecific Antibody Dis… https://t.co/7auLYjDMhF
Ligand highlights OmniChicken at Antibody Engineering and Therapeutics-Europe conference in presentation titled: “… https://t.co/Ft7N37SAQQ